

[Open Peer Review on Qeios](#)

# TGF-beta Receptor 1 Inhibitor PF-06952229

National Cancer Institute

## Source

National Cancer Institute. *TGF-beta Receptor 1 Inhibitor PF-06952229*. NCI Thesaurus. Code C160258.

An orally bioavailable inhibitor of transforming growth factor-beta receptor 1 (TGFβR1), with potential antineoplastic activity. Upon administration, TGF-betaR1 inhibitor PF-06952229 specifically targets and binds to TGFβR1, which prevents TGFβR1-mediated signal transduction. This abrogates TGFβR1-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFβR1-dependent proliferation of cancer cells. The TGFβ signaling pathway is often deregulated in tumors and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, and angiogenesis. It plays a key role in immunosuppression in the TME.